PA
HRTX icon

Parallel Advisors’s Heron Therapeutics HRTX Stock Holding History

Parallel Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160 Hold
200
– – ﹤0.01% 3760
2025
Q4 		$260 Hold
200
– – ﹤0.01% 3486
2025
Q3 		$252 Hold
200
– – ﹤0.01% 3422
2025
Q2 		$414 Hold
200
– – ﹤0.01% 3328
2025
Q1 		$440 Hold
200
– – ﹤0.01% 3253
2024
Q4 		$306 Hold
200
– – ﹤0.01% 3315
2024
Q3 		$398 Hold
200
– – ﹤0.01% 3214
2024
Q2 		$700 Hold
200
– – ﹤0.01% 3032
2024
Q1 		$554 Hold
200
– – ﹤0.01% 3037
2023
Q4 		$340 Hold
200
– – ﹤0.01% 3110
2023
Q3 		$206 Sell
200
-623
-76% -$887 ﹤0.01% 3228
2023
Q2 		$955 Hold
823
– – ﹤0.01% 2950
2023
Q1 		$1.24K Buy
823
+623
+312% +$1.56K ﹤0.01% 2903
2022
Q4 		$500 Hold
200
– – ﹤0.01% 3029
2022
Q3 		$1K Hold
200
– – ﹤0.01% 2922
2022
Q2 		$1K Hold
200
– – ﹤0.01% 2779
2022
Q1 		$1K Hold
200
– – ﹤0.01% 2761
2021
Q4 		$2K Hold
200
– – ﹤0.01% 2698
2021
Q3 		$2K Hold
200
– – ﹤0.01% 2690
2021
Q2 		$3K Hold
200
– – ﹤0.01% 2457
2021
Q1 		$3K Hold
200
– – ﹤0.01% 2369
2020
Q4 		$4K Hold
200
– – ﹤0.01% 2096
2020
Q3 		$3K Sell
200
-122
-38% -$1.9K ﹤0.01% 2186
2020
Q2 		$4K Buy
322
+122
+61% +$2K ﹤0.01% 2011
2020
Q1 		$2K Buy
+200
New +$3.76K ﹤0.01% 2133
2019
Q2 		– Sell
-1,685
Closed -$41K – 2364
2019
Q1 		$41K Buy
1,685
+1,200
+247% +$31.4K ﹤0.01% 923
2018
Q4 		$12K Buy
+485
New +$13.3K ﹤0.01% 1246
2017
Q3 		– Sell
-250
Closed -$4K – 2147
2017
Q2 		$4K Hold
250
– – ﹤0.01% 1670
2017
Q1 		$4K Hold
250
– – ﹤0.01% 1577
2016
Q4 		$3K Buy
+250
New +$3.92K ﹤0.01% 1527

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Parallel Advisors's HRTX Position: Q1 2026 in Review

Parallel Advisors held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 200 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #3760.

Parallel Advisors first reported a position in HRTX in Q4 2016 and has held it in 30 quarters since. The position peaked at $41K in Q1 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Parallel Advisors held 200 shares of Heron Therapeutics worth $160 as of Q1 2026.
  • Parallel Advisors left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3760 holding.
  • Parallel Advisors first reported a position in Heron Therapeutics in Q4 2016 and has held it in 30 quarters since.
  • Parallel Advisors's Heron Therapeutics position peaked at $41K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.